CHISUNGO-671, KEYTRUDA, Merck, NSCLC, Pembrolizumab
Neoadjuvant / adjuvant pembrolizumab inotenderwa neFDA kune inogadziriswa isiri-diki cell kenza yemapapu.
Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
Nhoroondo ye Array BioPharma Inc, binimetinib, Braftovi, encorafenib, Mektovi, Pfizer
Encorafenib ine binimetinib inotenderwa neFDA kuti irapwe metastatic isiri-diki cell cancer yemapapu ine BRAF V600E shanduko.
Chikafu neDrug Administration (FDA) yakatendera Encorafenib (Braftovi, Array BioPharma Inc., inotsigirwa nePfizer) uye binimetinib (Mektovi, Array BioPharma Inc.) muna Mbudzi 2023 semishonga inogona kushandiswa kugadzirisa.
ARROW muyedzo, Genentech, NSCLC, pralsetinib
Pralsetinib inotenderwa neFDA kune isiri-diki cell kenza yemapapu ine RET gene fusions.
Nyamavhuvhu 2023: Pralsetinib (Gavreto, Genentech, Inc.) yakapihwa mvumo nguva dzose neFood and Drug Administration yevarwere vakuru vane metastatic RET fusion-positive isiri diki cell lung cancer (NSCLC), sekutemerwa neFDA.
FDA, Zvokudya uye Drug Administration, KEYTRUDA, Merck, Pembrolizumab, platinum-based chemotherapy
Pembrolizumab inotenderwa neFDA seadjuvant kurapwa kune isiri-diki cell kenza yemapapu.
Kukadzi 2023: Yechikamu IB (T2a 4 cm), nhanho II, kana nhanho IIIA isiri diki cell cancer yemapapu, iyo Food and Drug Administration (FDA) yakabvumidza pembrolizumab (Keytruda, Merck) seadjuvant therapy mushure mekubviswa uye platinamu-based chemoth. ..
AstraZeneca Pharmaceuticals, durvalumab, Imjudo, NSCLC, POSEIDON, tremelimumab
Tremelimumab inotenderwa neFDA pamwe chete nedurvalumab uye platinum-based chemotherapy ye metastatic isiri-diki cell kenza yemapapu.
Mbudzi 2022: Musanganiswa we tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), uye platinum-based chemotherapy yakatenderwa neChikafu neDrug Administration yevakuru.
Libtayo, NCT03409614, NSCLC, platinum-based chemotherap, Regeneron Mishonga
Cemiplimab-rwlc inotenderwa neFDA pamwe chete neplatinamu-based chemotherapy kune isiri-diki cell cancer yemapapu.
Mbudzi 2022: Iko kusanganiswa kwe cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) uye platinum-based chemotherapy yevarwere vakuru vane yepamusoro isiri-diki cell kenza yemapapu (NSCLC) isina EGFR, ALK, kana ROS1 abnormalit.
am-trastuzumab deruxtecan-nxki, Daiichi Sankyo, Enhertu
Mvumo yekukurumidza inopihwa neFDA kune fam-trastuzumab deruxtecan-nxki yeHER2-mutant isiri-diki cell cancer yemapapu.
Nyamavhuvhu 2022: Kune varwere vakuru vane metastatic isiri-diki cell yemapapu cancer (NSCLC) vane mapundu ane shanduko inokonzeresa mesenchymal-epithelial transition (MET) exon 14 kusvetuka, sezvakaonekwa neFDA-yakatenderwa bvunzo, iyo Chikafu.
Capmatinib, NCT02414139, Nhoroondo ye Novartis Pharmaceuticals Corp, NSCLC, Tabrecta
Capmatinib inotenderwa kune metastatic isiri-diki cell kenza yemapapu
Nyamavhuvhu 2022: Kune varwere vakuru vane metastatic isiri-diki cell yemapapu cancer (NSCLC) vane mapundu ane shanduko inokonzeresa mesenchymal-epithelial transition (MET) exon 14 kusvetuka, sezvakaonekwa neFDA-yakatenderwa bvunzo, iyo Chikafu.
BMS, CHECKMATE-816, nivolumab, NSCLC, Wonderful
Neoadjuvant nivolumab uye platinum-doublet chemotherapy inotenderwa kwekutanga-nhanho isiri diki kenza yemapapu.
Kurume 2022: Munzvimbo yeNeoadjuvant, iyo FDA yakabvumidza nivolumab (Opdivo, Bristol-Myers Squibb Kambani) pamwe chete neplatinamu-doublet chemotherapy yevarwere vakuru vane rectable isiri-diki cell cancer yemapapu (NSCLC).
Atezolizumab, Genentech, NSCLC, Tecentriq, Ventana Medical Systems, VENTANA PD-L1
Atezolizumab inotenderwa neFDA seadjuvant kurapwa kune isiri-diki cell kenza yemapapu.
Nov 2021: Chikafu neDrug Administration yakabvumidza atezolizumab (Tecentriq, Genentech, Inc.) yekurapa adjuvant muvarwere vane nhanho II kusvika IIIA isiri-diki cell cancer yemapapu (NSCLC) ine mapundu ane PD-L1 kutaura o.